ReviewImaging manifestations of progressive multifocal leukoencephalopathy
Introduction
Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease caused by the reactivation of JC virus in immunocompromised patients. The name JC virus was derived from the initials of the patient from whose brain the virus was first isolated.1
Histopathologically, PML is characterized by extensive and progressive demyelination with notable absence of significant inflammatory response. The affected oligodendrocytes are enlarged and contain prominent intranuclear inclusion bodies.
With improved survival of immunocompromised patients and increased use of immunomodulatory medications for autoimmune/inflammatory diseases, radiologists are now more likely to encounter PML in routine clinical practice. The diagnosis is frequently considered for the first time based on imaging findings. Novel, more effective therapies for acquired immunodeficiency syndrome (AIDS) and PML have not only improved survival but have also altered the expected imaging features in PML. Newer imaging modes like diffusion-weighted imaging (DWI), diffusion tensor imaging (DTI), and magnetization transfer technique are being used to assess treated PML patients. In this article, we present a review of PML focusing on the radiological aspects of the disease.
Section snippets
Epidemiology
PML was originally described in patients with chronic diseases associated with compromised immune response, such as lymphoma, leukaemia, sarcoidosis, tuberculosis, and in patients with renal transplants during immunosuppressive therapy.2, 3, 4 A surge in PML occurred in the 1980s with the AIDS pandemic.5 PML has also been described in patients with many rheumatic and autoimmune diseases.6, 7 Immunosuppressive drugs related to development of PML include corticosteroids, chemotherapeutic agents,
Clinical features and diagnosis
Clinical symptoms and signs of PML are nonspecific. PML can be the initial AIDS-defining illness in up to 25% cases.21 Limb weakness, cognitive deficits, speech and visual difficulties, ataxia, seizures, and headache are the reported presenting symptoms, from most to least common.
Stereotactic brain biopsy is the reference standard for diagnosis, but it is not the preferred method due to its invasive nature. Cerebrospinal fluid polymerase chain reaction (CSF-PCR) for JC virus DNA is the method
CT
CT abnormalities in PML were first described in 1977. On CT, low-density lesions of central and convolutional white matter with scalloped borders are typically seen (Fig. 1). Lesions demonstrate no mass effect or contrast enhancement. With disease progression, PML lesions may show enlargement on CT, however, the temporal evolution of CT findings often lags behind the rate of clinical progression.30, 31 CT is less sensitive than magnetic resonance imaging (MRI) in the initial stages of PML.
MRI
The
Summary
The diagnosis of PML should be considered in any patient with immunosuppression who has multifocal white matter lesions with absence of mass effect and no or minimal contrast enhancement. Knowledge of typical and atypical imaging features of PML can be helpful in differential diagnosis from other infections and tumours that are also common in these patient populations. DWI, MR spectroscopy, and magnetization transfer have a complementary role to conventional MRI in terms of lesion
References (74)
- et al.
Cultivation of papova-like virus from human brain with progressive multifocal leucoencephalopathy
Lancet
(1971) - et al.
The association of progressive multifocal leukoencephalopathy and sarcoidosis
Chest
(1983) - et al.
Efficacy of camptothecin in progressive multifocal leucoencephalopathy
Lancet
(1997) Progressive multifocal leukoencephalopathy
Neurol Clin
(2008)- et al.
Progressive multifocal leukoencephalopathy in renal transplant recipients
Arch Intern Med
(1976) Progressive multifocal leukoencephalopathy
N Engl J Med
(1961)- et al.
Progressive multifocal leukoencephalopathy in a male homosexual with T-cell immune deficiency
N Engl J Med
(1982) - et al.
Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies
Ann Rheum Dis
(2008) - et al.
Progressive multifocal leukoencephalopathy in autoimmune disorders
Gut
(2009) Natalizumab
Drugs Today (Barc)
(2006)
Progressive multifocal leukoencephalopathy in a lymphoma patient with complete remission after treatment with cytostatics and rituximab: case report and review of the literature
Clin Neuropathol
Infratentorial progressive multifocal leukoencephalopathy in a patient treated with fludarabine and rituximab
Neurol Sci
Therapy: rituximab and PML risk-informed decisions needed!
Nat Rev Rheumatol
Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents
Eur J Clin Pharmacol
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 14–2004. A 66-year-old man with progressive neurologic deficits
N Engl J Med
Changing incidence of central nervous system diseases in the EuroSIDA cohort.
Ann Neurol
Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA)
J Neurovirol
Successful cidofovir therapy of progressive multifocal leukoencephalopathy preceding angioimmunoblastic T-cell lymphoma
Leuk Lymphoma
Progressive multifocal leukoencephalopathy: cidofovir therapy in three patients with underlying hematological disease
J Neurol
Treatment of progressive multifocal leukoencephalopathy associated with natalizumab
N Engl J Med
Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression
J Neurol Neurosurg Psychiatry
Progressive multifocal leukoencephalopathy in patients with HIV infection
J Neurovirol
Specific diagnosis of progressive multifocal leukoencephalopathy by polymerase chain reaction
J Infect Dis
Diagnostic value of detecting JC virus DNA in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy
J Clin Microbiol.
JC virus DNA in cerebrospinal fluid of human immunodeficiency virus-infected patients: predictive value for progressive multifocal leukoencephalopathy
Ann Neurol
Diagnosis of AIDS-related focal brain lesions: a decision-making analysis based on clinical and neuroradiologic characteristics combined with polymerase chain reaction assays in CSF
Neurology
JC virus infection of brain. [Published online ahead of print Mar 18, 2010]
AJNR Am J Neuroradiol
Reduced rate of diagnostic positive detection of JC virus DNA in cerebrospinal fluid in cases of suspected progressive multifocal leukoencephalopathy in the era of potent antiretroviral therapy
J Clin Microbiol.
Improved detection of JC virus in AIDS patients with progressive multifocal leukoencephalopathy by T-antigen specific fluorescence resonance energy transfer hybridization probe real-time PCR: evidence of diverse JC virus genotypes associated with progressive multifocal leukoencephalopathy in Southern Africa
J Med Virol
Diagnosis of progressive multifocal leukoencephalopathy by computed tomography
Radiology
Progressive multifocal leukoencephalopathy: clinical and radiographic features
Ann Neurol
MRI pattern of progressive multifocal leukoencephalopathy (PML) in AIDS. Pathological correlations
J Neuroradiol
MR imaging in progressive multifocal leukoencephalopathy
AJNR Am J Neuroradiol
Progressive multifocal leukoencephalopathy in AIDS: are there any MR findings useful to patient management and predictive of patient survival? AIDS Clinical Trials Group, 243 Team
AJNR Am J Neuroradiol
Progressive multifocal leukoencephalopathy in 47 HIV-seropositive patients: neuroimaging with clinical and pathologic correlation
Radiology
Progressive multifocal leukoencephalopathy limited to the brain stem
Neuroradiology
MRI in PML: bilateral medullary lesions
Neurology
Cited by (101)
Infectious Meningitis and Encephalitis
2022, Neurologic ClinicsFour cases of progressive multifocal leukoencephalopathy in iatrogenic immunocompromised patients
2020, eNeurologicalSciCitation Excerpt :MRI lesions appear hypointense on T1w images and hyperintense on T2w and FLAIR images, with borders less defined toward the WM [7,15–19]. DWI characteristics are phase-specific: the advancing edge of the newer lesions shows diffusion restriction on DWI due to oligodendrocytes swelling and a low ADC, but progressively DWI signal decreases, ADC value increases, and Diffusion Tensor Imaging (DTI) shows an increased diffusivity with decreased anisotropy [16,20–22]. PML lesions classically do not exhibit mass effect, nor contrast enhancement, although punctate and/or rim-like contrast enhancement has been described both in HIV-positive and HIV-negative PML patients [17–19,23].
Dynamic expression of JC virus in urine and its relationship to serostatus
2020, Multiple Sclerosis and Related DisordersMRI characteristics of chemotherapy-related central neurotoxicity: a pictorial review
2024, Insights into Imaging